GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Issue 2 (4th March 2021)

• Record Type: Journal Article
• Authors: Lisby, Amanda N.; Flickinger, John C.; Bashir, Babar; Weindorfer, Megan; Shelukar, Sanjna; Crutcher, Madison; Snook, Adam E.; Waldman, Scott A.
• Is Part Of: Expert review of precision medicine and drug development. Volume 6:Issue 2(2021)
• Page Start: 117
• Page End: 129
• Publication Date: 2021-03-04
• Subjects: Antibody Therapy -- biomarker -- cancer Vaccine -- colorectal Cancer -- car-T Cell Therapy -- guanylyl Cyclase C -- gucy2c; Personalized medicine -- Periodicals; Drug development -- Periodicals; 615.19005
• DOI: 10.1080/23808993.2021.1876518
• Languages: English
• ISSNs: 2380-8993

Abstract

ABSTRACT: Introduction: Colorectal cancer (CRC) is one of the most-deadly malignancies worldwide. Current therapeutic regimens for CRC patients are relatively generic, based primarily on disease type and stage, with little variation. As the field of molecular oncology advances, so too must therapeutic management of CRC. Understanding molecular heterogeneity has led to a new-found promotion for precision therapy in CRC; underlining the diversity of molecularly targeted therapies based on individual tumor characteristics. Areas covered: We review current approaches for the treatment of CRC and discuss the potential of precision therapy in advanced CRC. We highlight the utility of the intestinal protein guanylyl cyclase C (GUCY2C), as a multi-purpose biomarker and unique therapeutic target. Here, we summarize current GUCY2C-targeted approaches for treatment of CRC. Expert opinion: The GUCY2C biomarker has multi-faceted utility in medicine. Developmental investment of GUCY2C as a diagnostic and therapeutic biomarker offers a variety of options taking the molecular characteristics of cancer into account. From GUCY2C-targeted therapies, namely cancer vaccines, CAR-T cells, and monoclonal antibodies, to GUCY2C agonists for chemoprevention in those who are at high risk for developing colorectal cancer, the utility of this protein provides many avenues for exploration with significance in the field of precision medicine.